Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Pallavi Madhiraju- September 20, 2024 0

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More

Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!

Pallavi Madhiraju- September 11, 2024 0

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following the release of positive overall survival data ... Read More

Roche reports setback in lung cancer study with tiragolumab and tecentriq combination

Pallavi Madhiraju- July 7, 2024 0

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More

Hinova Pharmaceuticals’ HP518 gets FDA fast track designation in triple-negative breast cancer

Pallavi Madhiraju- July 6, 2024 0

Hinova Pharmaceuticals Inc. (688302.SH), a trailblazer in the biopharmaceutical industry, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast ... Read More

Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma

Pallavi Madhiraju- July 5, 2024 0

Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More

FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment

Pallavi Madhiraju- June 16, 2024 0

Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of BLINCYTO (blinatumomab) for the consolidation phase ... Read More

Zentalis Pharmaceuticals reports promising results from Phase 1 trial of azenosertib, gemcitabine combo

Pallavi Madhiraju- May 25, 2024 0

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final results of its Phase 1 trial combining ... Read More

Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study

Pallavi Madhiraju- May 21, 2024 0

Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in ... Read More

Setback for Bristol Myers Squibb: CheckMate -73L trial fails to meet endpoint

Pallavi Madhiraju- May 12, 2024 0

Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients ... Read More

Innovent Biologics showcases promising preclinical data at AACR 2024

Pallavi Madhiraju- April 8, 2024 0

In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More